Adlai Nortye Group(NASDAQ) ANL

Market Cap$807.01M

Since IPO (2023)-8%

5 YearN/A

1 Year+738%

1 Month+10%

Premium Feature

Moneyball Superscore

39/100

$13.89

+1.06%

+0.14Today

Adlai Nortye Group last closing stock price
Metric	Price	Date
Last close	USD 13.74	2026-08-25

Adlai Nortye Group stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-2.97%	USD 14.16	2026-08-18
1 month	+9.92%	USD 12.50	2026-07-24
3 month	+24.91%	USD 11.00	2026-05-27
Year to date	+867.61%	USD 1.42	2025-12-31
1 year	+737.8%	USD 1.64	2025-08-25
Since inception	-8.4%	USD 15.00	2023-09-29

Adlai Nortye Group Financials at a Glance

Market Cap

$807.01M

Revenue (TTM)

$19.68M

Net Income (TTM)

-$22.53M

EPS (TTM)

-$0.54

P/E Ratio

-25.30

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$13.89

Volume

12,576.252

Open

$13.70

Price

$13.89

Volume

12,576.252

Open

$13.70

Previous Close

$13.74

Daily Range

$13.50 - $13.98

52-Week Range

$0.88 - $17.25

Estimated Earnings Date

Mar 3, 2027

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$13.89

Volume

12,576.252

Open

$13.70

Previous Close

$13.74

Daily Range

$13.50 - $13.98

52-Week Range

$0.88 - $17.25

Estimated Earnings Date

Mar 3, 2027

ANL News

No articles available.

ANL: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Adlai Nortye Group

Adlai Nortye Ltd. is a biopharmaceutical company that focuses on developing innovative oncology therapies. Through strategic research, partnerships, and cutting-edge technology, the company aims to provide transformative cancer treatments worldwide.

Products and Services

Development of oncology therapies using immunotherapy techniques

Utilization of kinase inhibitors for cancer treatment

Supportive collaborations with global research institutions

What Makes Adlai Nortye Ltd. Special

Adlai Nortye Ltd. stands out due to its cutting-edge immunotherapy and kinase inhibitor strategies that target cancer treatment. The company builds robust partnerships to enhance its research and development capabilities, which accelerates progress and innovation in its therapeutic advancements.

Five Things You Need to Know

Adlai Nortye is focused on the precision medicine landscape in oncology.

The company leverages immunotherapy to treat cancer effectively.

It maintains strategic alliances with leading global research institutions.

Adlai Nortye's leadership has deep industry expertise in biopharma.

The company prioritizes the expansion and diversification of its product pipeline through in-licensing opportunities.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

109

CEO

Yang Lu, EMBA

Website

www.adlainortye.com

Headquarters

North Brunswick, NJ 08902, US

ANL Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-113.28%

Net Income Margin

-114.48%

Return on Equity

-21.82%

Return on Capital

-197.73%

Return on Assets

-9.07%

Earnings Yield

-3.95%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$807.01M

Shares Outstanding

58.73M

Volume

12.58K

Avg. Volume

175.25K

Financials (TTM)

Gross Profit

$19.68M

Operating Income

-$22.29M

EBITDA

-$21.47M

Operating Cash Flow

-$57.97M

Capital Expenditure

-$280.50K

Free Cash Flow

-$58.25M

Cash & ST Invst.

$232.82M

Total Debt

$26.70M

Adlai Nortye Group Performance Analysis

Adlai Nortye Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 0	N/A
2023	2023-12-31	USD 0	N/A
2024	2024-12-31	USD 0	N/A
2025	2025-12-31	USD 5,013,224	N/A

Adlai Nortye Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	193.6%
Q2	2026-06-30	N/A

Adlai Nortye Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -1.80	3.5%
2023	2023-12-31	USD -7.55	320.1%
2024	2024-12-31	USD -1.63	-78.5%
2025	2025-12-31	USD -1.11	-31.5%

Adlai Nortye Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	79.3%
Q2	2026-06-30	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$7.34M

N/A

Gross Profit

$7.34M

N/A

Gross Margin

100.00%

N/A

Market Cap

$807.01M

N/A

Market Cap/Employee

$7.40M

N/A

Employees

109

N/A

Net Income

-$2.67M

+80.7%

EBITDA

-$2.69M

+81.2%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$232.82M

+427.4%

Total Debt

$26.70M

-40.1%

Accounts Receivable

$264.00K

-91.5%

Inventory

$0.00

N/A

Long Term Debt

$8.31M

+3133.5%

Short Term Debt

$18.39M

-58.5%

Return on Assets

-9.07%

N/A

Return on Invested Capital

-9.99%

N/A

Free Cash Flow

-$7.68M

+46.1%

Operating Cash Flow

-$7.68M

+45.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ADAPAdaptimmune Therapeutics plc

ADAPAdaptimmune Therapeutics plc$0.05-3.00%

APLMApollomics, Inc.

APLMApollomics, Inc.$26.50+2.42%

LPCNLipocine Inc.

LPCNLipocine Inc.$2.27+5.35%

BLRXBioLineRx Ltd.

BLRXBioLineRx Ltd.$3.00+5.26%

AIMDAinos, Inc.

AIMDAinos, Inc.$1.44-0.69%

ICUSeaStar Medical Holding Corporation

ICUSeaStar Medical Holding Corporation$3.21+0.94%

ADTXAditxt, Inc.

ADTXAditxt, Inc.$0.00-26.15%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

CRECre8 Enterprise

CRECre8 Enterprise$6.60+1.57%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.50-0.01%

NVDANvidia

NVDANvidia$210.97-0.01%

DAICCid HoldCo

DAICCid HoldCo$5.15+0.33%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$8.81-0.03%

SNAPSnap

SNAPSnap$5.52-0.07%

INTCIntel

INTCIntel$86.64-0.01%

Questions About ANL

What is the current price of Adlai Nortye Group?

Adlai Nortye Group is trading at $13.89 per share.

What is the 52-week range for Adlai Nortye Group?

Over the past 52 weeks, Adlai Nortye Group has traded between $0.88 and $17.25.

How much debt does Adlai Nortye Group have?

As of the most recent reporting period, Adlai Nortye Group reported total debt of $26.38M.

How much cash does Adlai Nortye Group have on hand?

Adlai Nortye Group reported $23.79M in cash and cash equivalents in its most recent financial results.

What is Adlai Nortye Group’s dividend yield?

Adlai Nortye Group does not currently have a dividend yield.

Adlai Nortye Group(NASDAQ) ANL

Adlai Nortye Group Financials at a Glance

ANL News

ANL: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Adlai Nortye Group

Products and Services

What Makes Adlai Nortye Ltd. Special

Five Things You Need to Know

ANL Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Adlai Nortye Group Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ANL

What is the current price of Adlai Nortye Group?

What is the 52-week range for Adlai Nortye Group?

How much debt does Adlai Nortye Group have?

How much cash does Adlai Nortye Group have on hand?

What is Adlai Nortye Group’s dividend yield?

Premium Investing Services